HKEX Stock Code: 01093English|繁體|简体
Home > Investor Relations > Announcements & Notices
Announcements & Notices
Dec
31
LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION
Dec
28
RESIGNATION OF NON-EXECUTIVE DIRECTOR AND INDEPENDENT NON-EXECUTIVE DIRECTOR, CHANGE OF COMPANY SECRETARY AND CHANGE OF BOARD COMMITTEES
Dec
28
INSIDE INFORMATION - ADJUSTMENT TO THE MEDICAL INSURANCE REIMBURSEMENT BASIS
Dec
18
Overseas Regulatory Announcement (Chinese version)
Dec
18
CONTINUING CONNECTED TRANSACTIONS - RENEWAL OF STEAM SUPPLY AGREEMENT
Dec
18
VOLUNTARY ANNOUNCEMENT - ABSTRACT OF CLINICAL TRIAL DATA OF MITOXANTRONE HYDROCHLORIDE LIPOSOME FOR RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA AND EXTRANODAL NK/T-CELL LYMPHOMA PRESENTED AT 2020 ASH ANNUAL MEETING
Dec
02
VOLUNTARY ANNOUNCEMENT - INVESTIGATIONAL NEW DRUG NBL-015 GRANTED ORPHAN-DRUG DESIGNATION BY THE U.S. FDA
Dec
01
VOLUNTARY ANNOUNCEMENT - INVESTIGATIONAL NEW DRUG "ALMB-0166" OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
Nov
24
VOLUNTARY ANNOUNCEMENT - INVESTIGATIONAL FIRST-IN-CLASS PRODUCT SYSA1801 GRANTED ORPHAN-DRUG DESIGNATION BY THE U.S. FDA
Nov
24
LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION
Nov
23
APPOINTMENT OF EXECUTIVE DIRECTOR
Nov
23
QUARTERLY RESULTS FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2020
Nov
11
DATE OF BOARD MEETING
Nov
03
VOLUNTARY ANNOUNCEMENT - INNOVATIVE DRUG "SYHA1813 ORAL SOLUTIONS" OBTAINS CLINICAL TRIAL APPROVAL
Oct
28
VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN THE PHASE 1 CLINICAL TRIAL OF INVESTIGATIONAL NEW DRUG "ALMB-0168"
Oct
22
INSIDE INFORMATION - PRINCIPAL FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE THIRD QUARTER OF 2020
Oct
12
POLL RESULTS OF EXTRAORDINARY GENERAL MEETING HELD ON 12 OCTOBER 2020
Sep
22
NOTICE OF EXTRAORDINARY GENERAL MEETING
Sep
17
VOLUNTARY ANNOUNCEMENT - "DOCETAXEL FOR INJECTION (ALBUMIN-BOUND)" OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Sep
15
VOLUNTARY ANNOUNCEMENT - INVESTIGATIONAL NEW DRUG "ALMB-0168" OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
Aug
28
CONTINUING CONNECTED TRANSACTIONS - RENEWAL OF STEAM SUPPLY AGREEMENT
Aug
26
2020 INTERIM RESULTS ANNOUNCEMENT
Aug
25
VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF NEW DRUG APPLICATION FOR "MITOXANTRONE HYDROCHLORIDE LIPOSOME INJECTION"
Aug
24
VOLUNTARY ANNOUNCEMENT - ONCOLOGY DRUG "SYHA1815 TABLETS" OBTAINS CLINICAL TRIAL APPROVAL
Aug
20
INSIDE INFORMATION - PRINCIPAL FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD . FOR THE HALF YEAR ENDED 30 JUNE 2020
Aug
14
DATE OF BOARD MEETING
Aug
14
LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION
Aug
14
RESIGNATION OF DIRECTOR
Jul
27
VOLUNTARY ANNOUNCEMENT - "DULOXETINE HYDROCHLORIDE ENTERIC CAPSULES" OBTAINS DRUG REGISTRATION APPROVAL
Jul
21
VOLUNTARY ANNOUNCEMENT - "MEMANTINE HYDROCHLORIDE TABLETS" OBTAINS DRUG REGISTRATION APPROVAL
Jul
21
VOLUNTARY ANNOUNCEMENT - "ACARBOSE TABLETS" OBTAINS DRUG REGISTRATION APPROVAL
Jul
14
VOLUNTARY ANNOUNCEMENT - "CELECOXIB CAPSULES" OBTAINS DRUG REGISTRATION APPROVAL
Jun
23
VOLUNTARY ANNOUNCEMENT - "BORTEZOMIB FOR INJECTION" OBTAINS DRUG REGISTRATION APPROVAL
Jun
15
POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON 15 JUNE 2020
May
28
VOLUNTARY ANNOUNCEMENT - INNOVATIVE DRUG "SYHA1805" OBTAINS CLINICAL TRIAL APPROVAL
May
27
INSIDE INFORMATION - PROPOSED ISSUE OF RMB SHARES OR CHINESE DEPOSITARY RECEIPTS AND LISTING ON THE SCI-TECH BOARD OF THE SHANGHAI STOCK EXCHANGE
May
27
QUARTERLY RESULTS FOR THE THREE MONTHS ENDED 31 MARCH 2020
May
19
VOLUNTARY ANNOUNCEMENT - "DOCETAXEL FOR INJECTION (ALBUMIN-BOUND)" OBTAINS CLINICAL TRIAL APPROVAL
May
15
DATE OF BOARD MEETING
May
04
VOLUNTARY ANNOUNCEMENT - "ORNITHINE ASPARTATE INJECTION" OBTAINS DRUG REGISTRATION APPROVAL
Apr
27
NOTICE OF ANNUAL GENERAL MEETING
Apr
26
INSIDE INFORMATION - PRINCIPAL FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE THREE MONTHS ENDED 31 MARCH 2020
Mar
30
ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2019
Mar
22
INSIDE INFORMATION - INDICATIVE RESULTS OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE THREE MONTHS ENDED 31 MARCH 2020
Mar
22
INSIDE INFORMATION - PRINCIPAL FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE YEAR ENDED 31 DECEMBER 2019
Mar
18
DATE OF BOARD MEETING
Mar
09
VOLUNTARY ANNOUNCEMENT - DRUG REGISTRATION APPROVAL OF THE GROUP'S "RIVAROXABAN TABLETS"
Feb
25
VOLUNTARY ANNOUNCEMENT - DRUG REGISTRATION APPROVAL OF THE GROUP'S "MONTELUKAST SODIUM TABLETS AND CHEWABLE TABLETS"
Feb
24
INSIDE INFORMATION - PRELIMINARY RESULTS OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE YEAR ENDED 31 DECEMBER 2019
Feb
24
VOLUNTARY ANNOUNCEMENT - INVESTIGATIONAL NEW DRUG ALMB-0168 WAS GRANTED CLINICAL TRIAL APPROVAL IN AUSTRALIA
Jan
22
INSIDE INFORMATION - INDICATIVE RESULTS OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE YEAR ENDED 31 DECEMBER 2019
Jan
19
VOLUNTARY ANNOUNCEMENT - SELECTION RESULTS OF NATIONAL CENTRALISED MEDICINES PROCUREMENT
Jan
02
VOLUNTARY ANNOUNCEMENT - DRUG REGISTRATION APPROVAL OF THE GROUP'S "PRAMIPEXOLE DIHYDROCHLORIDE TABLETS"
Jan
02
VOLUNTARY ANNOUNCEMENT - DRUG REGISTRATION APPROVAL OF THE GROUP'S "SUNITINIB MALATE CAPSULES"

Please download the latest "Acrobat Reader" to view the PDF.

© Copyright 2025 CSPC Pharmaceutical Group Limited. All Rights Reserved.
Disclaimer